Skip to content

Postoperative effects of combined use of terazosin and nifedipine in treatment of distal ureteral stones by transurethral ureteroscopic lithotripsy

Postoperative effects of combined use of terazosin and nifedipine in treatment of distal ureteral stones by transurethral ureteroscopic lithotripsy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025212
Enrollment
Unknown
Registered
2019-08-16
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ureteral stone

Interventions

Experimental group:To drink 2000~3000 ml water every day and received ciprofloxacin (0.5 g, twice/d) for 7 d. Patients received both terazosin (2 mg, once/d) and nifedipine (10 mg, three times/d) ever
Terazosin group:To drink 2000~3000 ml water every day and received ciprofloxacin (0.5 g, twice/d) for 7 d. Patients received terazosin (2 mg, once/d) every day for 7 d.
Control group:all patients were asked to drink 2000~3000 ml water every day and received ciprofloxacin (0.5 g, twice/d) for 7 d.

Sponsors

The First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: All patients were diagnosed as distal ureteral stones by image methods including CT, kidney and upper bladder (KUB) X ray or intravenous pyelography. The stones were at the inner wall segment of ureter and bladder or near the bladder wall. The distance between stone center and ureteral orifice was > 3 cm and sinus disjunction > 3 cm on the affected side.

Exclusion criteria

Exclusion criteria: The diameter of stones > 1 cm, patients with renal insufficiency, patients with bilateral ureteral calculi or multiple ureteral calculi, patients with history of pelvic and ureteral surgery, patients with other diseases of urinary system such as infection, tumor, patients who received a receptor antagonist or calcium antagonist within 1 months before the study and patients who lost follow-up during the study.

Design outcomes

Primary

MeasureTime frame
stone discharge rate;discharge time;

Secondary

MeasureTime frame
pain;Prostate function;

Countries

China

Contacts

Public ContactJu Min

The First Hospital of China Medical University

13840003695@163.com+86 13840003695

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026